上海医药利伐沙班片获马来西亚药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for the marketing of its rivaroxaban tablets, indicating a significant step in expanding its market presence in Malaysia [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, has obtained a drug registration certificate for rivaroxaban tablets from the NPRA [1] - The approved rivaroxaban tablets are available in three specifications: 10mg, 15mg, and 20mg [1] Industry Summary - Rivaroxaban is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) in acutely ill patients [1]